Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis
Restricted accessResearch articleFirst published online April, 2019
Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis
Contrast-induced acute kidney injury (CI-AKI) is a common complication of iodinated contrast medium administration during cardiac catheterization. Statin treatment has been shown to be associated with reduced risk of CI-AKI; however, the results are inconsistent, especially for patients with chronic kidney disease (CKD). Thus, we conducted a network meta-analysis to evaluate the effects of statins in the prevention of CI-AKI. We systematically searched several databases (including, Embase, PubMed, the Cochrane Library, and ClinicalTrials.gov) from inception to January 31, 2018. The primary outcome was occurrence of CI-AKI in patients with CKD undergoing cardiac catheterization. Both pairwise and network meta-analysis were performed. Finally, 21 randomized controlled trials with a total of 6385 patients were included. Results showed that statin loading before contrast administration was associated with a significantly reduced risk of CI-AKI in patients with CKD undergoing cardiac catheterization (odds ratio: 0.46; P < .05). Atorvastatin and rosuvastatin administered at high dose may be the most effective treatments to reduce incidence of CI-AKI, with no difference between these 2 agents.
TsaiTTPatelUDChangTI. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1–9.
2.
AbaciOHarmankayaOKocasB. Long-term follow-up of patients at high risk for nephropathy after contrast exposure. Angiology. 2015;66(6):514–8.
3.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Contrast-induced nephropathy: an “all or none” phenomenon?Angiology. 2015;66(6):508–13.
4.
WindeckerSKolhPAlfonsoF. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10(9):1024–94.
5.
HanYZhuGHanL. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63(1):62–70.
6.
BediODhawanVSharmaPLKumarP. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(7):695–712.
7.
SeeligerESendeskiMRihalCSPerssonPB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.
8.
AkyuzSYaylakBAltaySKasikciogluHCamN. The role of statins in preventing contrast-induced acute kidney injury: a narrative review. Angiology. 2015;66(8):701–7.
9.
HigginsJGreenS, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. http://handbook.cochrane.org. Updated March 2011. Accessed February 21, 2018.
10.
DiasSWeltonNJCaldwellDMAdesAE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932–44.
11.
AbaciOArat OzkanAKocasC. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 2015;115(7):867–71.
12.
JoSHKooBKParkJS. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J. 2008;155(3):499.e1–8.
13.
LeonciniMTosoAMaioliMTropeanoFVillaniSBellandiF. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(1):71–9.
14.
OliveiraMS deMartinsKBACostaJRJr. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users. Revista Brasileira De Cardiol Invas. 2012;20(3):303–8.
15.
PattiGRicottiniENuscaA. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial). Am J Cardiol. 2011;108(1):1–7.
16.
QuintavalleCFioreDDe MiccoF. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–16.
17.
TosoAMaioliMLeonciniM. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105(3):288–92.
18.
LiuYTanNChenYY. The effect of treatment with atorvastatin in different dosage on contrast-induced nephropathy after percutaneous coronary intervention in patients with chronic kidney disease [in Chinese]. Chin J Interv Cardiol. 2011;19:218–22.
19.
LuSZhangJY. The effect of rosuvastatin treatment on contrast-induced acute kidney injury in patients with chronic kidney disease [in Chinese]. Chin J Pract Med. 2015;42:68–9.
20.
ZhangWYYangSCFuNK. The preventive effect of contrast induced nephropathy in elderly coronary heart disease patients with renal insufficiency after percutaneous coronary intervention treated by atorvastatin [in Chinese]. Mod Med J China. 2016;18:1–5.
21.
ZhangXBTangFYWangGHZhangLQYangWWJiXQ. The study of atorvastatin combined with hydration to prevent contrast-induced nephropathy [in Chinese]. Chin J Gen Pract. 2011;10:258–9.
22.
ZengCLiSNChenPALiuZLeiXM. Effects of administer large dose statins combined with hydration on prevention of contrast induced nephropathy in elderly patients with chronic renal insufficiency [in Chinese]. Chin J Cardiovasc Res. 2013;11:697–700.
23.
LiDTLiSBLiTCChenY. Clinical effects of strengthen atorvastatin on contrast-induced nephropathy after percutaneous coronary intervention [in Chinese]. Chin J Clin. 2013;7:6286–8.
24.
YangLXLiYWZhangJTLiuM. The effect of treatment with atorvastain in different dosage on contrast induced nephropathy in patients with diabetic nephropathy after percutaneous coronary intervention [in Chinese]. Chine Remed Clin. 2015;15:1646–8.
25.
WangWHHouXLWangHTSongXWFuCY. Clinical effects of strengthen atorvastatin on contrast-induced nephropathy after percutaneous coronary intervention in patient with renal insufficiency [in Chinese]. Henan Tradit Chin Med. 2013;33:199–200.
26.
TianKXRenYHSuSDXiaoKYYeTCDengCJ. Protective effects of atorvastatin on contrast-induced nephropathy in elderly patients with chronic kidney disease [in Chinese]. World Chin Med. 2016;11:2094–5.
27.
JiFJCongHLYangSCFuNK. Protective effects of strengthen atorvastatin on contrast-induced nephropathy after percutaneous coronary intervention in patient with hypertension and chronic kidney disease [in Chinese]. Chin J Hypertens. 2013;21:577–81.
28.
ZhaoJJHeYXueFLiN. Statins in prevention of contrast-induced nephropathy in patients with coronary heart disease and renal insufficiency undergoing percutaneous coronary intervention [in Chinese]. Int Med Health Guid News. 2012;18:919–23.
29.
ZhengSYYaoJPLiSBZhouXH. Rosuvastatin control CIAKI risk on diabetic patients with mild to moderate CKD and diuretics at high risk [in Chinese]. Chin J Biochem Pharm. 2015;35:139–42.
30.
ChenHLiSHDengYQXiongQZ. Effects of atorvastatin on contrast-induced nephropathy in elderly patients with moderate to severe CKD [in Chinese]. Chin J Gerontol. 2016;36:1690–2.
31.
CiprianiAHigginsJPGeddesJRSalantiG. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–7.
32.
LuGAdesAE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–24.
33.
AurelioADuranteA. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014;128(1):62–72.
34.
UzunhasanIYildizAArslanS. Contrast-induced acute kidney injury is associated with long-term adverse events in patients with acute coronary syndrome. Angiology. 2017;68(7):621–6.
35.
Biondi-ZoccaiGLotrionteMThomsenHS. Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis. Int J Cardiol. 2014;172(2):375–80.
36.
PisaniASabbatiniMRiccioE. Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clin Exp Nephrol. 2014;18(3):424–31.
37.
WindpesslMKronbichlerA. Pro: contrast-induced nephropathy-should we try to avoid contrast media in patients with chronic kidney disease?Nephrol Dial Transpl. 2018;33(8):1317–9.
38.
EwingMJEidtJF. CON: contrast-induced nephropathy-should we try to avoid contrast media in patients with chronic kidney disease?Nephrol Dial Transpl. 2018;33(8):1320–2.
AlmutiKRimawiRSpevackDOstfeldRJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006;109(1):7–15.
41.
TawfikMKGhattasMHAbo-ElmattyDMAbdel-AzizNA. Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction. Eur Rev Med Pharmacol Sci. 2010;14(6):499–506.
42.
LiuYLiuYHTanN. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014;9(10):e111124.
43.
FerreiraTSLanzettiMBarrosoMV. Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation. 2014;37(5):1355–65.
44.
RidkerPMMacFadyenJCressmanMGlynnRJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266–73.
45.
BonnetJMcPhersonRTedguiA. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008;30(12):2298–313.
46.
XinweiJXianghuaFJingZ. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009;104(4):519–24.
47.
DulakJLobodaAJazwaA. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005;12(5-6):233–41.
48.
Abou-ShoushaSAYoussefAI. Interleukin-2 regulatory effect on P-selectin and interleukin-8 production in patients with chronic renal failure. Egypt J Immunol. 2006;13(1):11–8.
49.
PistolesiVRegolistiGMorabitoS. Contrast medium induced acute kidney injury: a narrative review. J Nephrol. 2018;31(6):797–812.
50.
BonettiPOLermanLONapoliCLermanA. Statin effects beyond lipid lowering—are they clinically relevant?Eur Heart J. 2003;24(3):225–48.
51.
MossanenJCPrachtJJansenTU. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. Int J Mol Sci. 2017;18(8):1662–73.
